EN
Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
$12.62 +7.91% (+$0.93)
1M -5.33%
Market Cap $366.8M
P/E Ratio -
Div. Yield -
ROE 61.84%
Bulios Fair Price
$15.86
25.7% upside
Current Price
$12.62
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ENTA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
43 /100
Fair P/B 3.63x
P/S 5.62x
PEG N/A
Growth
0 /100
Declining Book val. growth 41.38%
Rev. growth 8.82%
FCF growth N/A
Profitability
20 /100
Weak FCF margin 56.60%
Op. margin 89.99%
Gross margin 98.15%
Quality
3 /100
Poor Asset turnover 0.22x
ROA 21.30%
ROIC 23.85%
Debt
60 /100
Moderate Current ratio 3.76x
Int. coverage -3.89x
Debt/Equity 0.55x
Stability
82 /100
Stable Profitable years 0
EPS volatility 19.03%
Beta 0.94x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ENTA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jay R. Luly
Employees
120
Headquarters
Watertown
Upcoming events
16 NOV
Earnings
Upcoming earnings report